Pharmacokinetic based adjustment of lidocaine antiarrhythmic schedule
Administration of lidocaine, 200 mg/day i.m. or 275 mg orally, decreased sudden death after myocardial infarct (from 20.7% to 10.3%) although such schedules are not considered adequate to guarantee efficient plasma levels. Inclusion of lidocaine in a polyethylene matrix assured a slow release and co...
Gespeichert in:
| Veröffentlicht in: | European journal of drug metabolism and pharmacokinetics 1994-01, Vol.19 (1), p.33-36 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 36 |
|---|---|
| container_issue | 1 |
| container_start_page | 33 |
| container_title | European journal of drug metabolism and pharmacokinetics |
| container_volume | 19 |
| creator | VOICU, V MIRCIOIU, C JINGA, M IONESCU, M BURCEA, X IONESCU, D. D LUPESCU, G |
| description | Administration of lidocaine, 200 mg/day i.m. or 275 mg orally, decreased sudden death after myocardial infarct (from 20.7% to 10.3%) although such schedules are not considered adequate to guarantee efficient plasma levels. Inclusion of lidocaine in a polyethylene matrix assured a slow release and complete disappearance of known side effects. Lidocaine was administered 200 mg intramuscularly to hospitalized patients every 6 h or 275 mg oral tablets to healthy volunteers every 8 h and plasma levels evaluated. Plasma levels after oral administration to healthy volunteers showed a great variability, so that it was not possible to draw a statistically significant conclusion about the accumulation of lidocaine in a period of 1 week. In coronary artery disease patients, plasma levels slowly increased with time, but clinical signs indicated, in some cases, a much more rapid accumulation. The therapeutic efficiency at low repeated doses was explained as a consequence of a slow accumulation on the one hand and of the addition of the action of MEGX, the major metabolite of lidocaine, on the other hand. |
| doi_str_mv | 10.1007/BF03188820 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_76808028</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>76808028</sourcerecordid><originalsourceid>FETCH-LOGICAL-c311t-a9288b4df2aacd2f88e67cebe39c399cf957e009bf9e31c8eba9e1a07855444a3</originalsourceid><addsrcrecordid>eNpF0E1Lw0AQBuBFlFpqL96FHMSDEJ3dTbK7Ry2tCgU96DlMNhOSmo-6mxz674001LnMYR5ehpexaw4PHEA9Pm9Acq21gDM2FxxUCFzDOZuDVDpUJkku2dL7HYwjtYnjZMZmysQqisycrT9KdA3a7rtqqa9skKGnPMB8N_i-obYPuiKoq7yzOIIA275C58pDXzYj9rakfKjpil0UWHtaTnvBvjbrz9VruH1_eVs9bUMrOe9DNELrLMoLgWhzUWhNibKUkTRWGmOL8SsCMFlhSHKrKUNDHEHpOI6iCOWC3R1z9677Gcj3aVN5S3WNLXWDT1WiQYPQI7w_Qus67x0V6d5VDbpDyiH9qy39r23EN1PqkDWUn-hU0ni_ne7oLdaFw9ZW_sQiLoSOhfwFbux0sw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>76808028</pqid></control><display><type>article</type><title>Pharmacokinetic based adjustment of lidocaine antiarrhythmic schedule</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>VOICU, V ; MIRCIOIU, C ; JINGA, M ; IONESCU, M ; BURCEA, X ; IONESCU, D. D ; LUPESCU, G</creator><creatorcontrib>VOICU, V ; MIRCIOIU, C ; JINGA, M ; IONESCU, M ; BURCEA, X ; IONESCU, D. D ; LUPESCU, G</creatorcontrib><description>Administration of lidocaine, 200 mg/day i.m. or 275 mg orally, decreased sudden death after myocardial infarct (from 20.7% to 10.3%) although such schedules are not considered adequate to guarantee efficient plasma levels. Inclusion of lidocaine in a polyethylene matrix assured a slow release and complete disappearance of known side effects. Lidocaine was administered 200 mg intramuscularly to hospitalized patients every 6 h or 275 mg oral tablets to healthy volunteers every 8 h and plasma levels evaluated. Plasma levels after oral administration to healthy volunteers showed a great variability, so that it was not possible to draw a statistically significant conclusion about the accumulation of lidocaine in a period of 1 week. In coronary artery disease patients, plasma levels slowly increased with time, but clinical signs indicated, in some cases, a much more rapid accumulation. The therapeutic efficiency at low repeated doses was explained as a consequence of a slow accumulation on the one hand and of the addition of the action of MEGX, the major metabolite of lidocaine, on the other hand.</description><identifier>ISSN: 0378-7966</identifier><identifier>EISSN: 2107-0180</identifier><identifier>DOI: 10.1007/BF03188820</identifier><identifier>PMID: 7957449</identifier><language>eng</language><publisher>Genève: Médecine et hygiène</publisher><subject>Antiarythmic agents ; Arrhythmias, Cardiac - complications ; Arrhythmias, Cardiac - drug therapy ; Biological and medical sciences ; Cardiovascular system ; Chromatography, Gas ; Death, Sudden, Cardiac - prevention & control ; Delayed-Action Preparations ; Drug Administration Schedule ; Humans ; Injections, Intramuscular ; Lidocaine - administration & dosage ; Lidocaine - pharmacokinetics ; Lidocaine - therapeutic use ; Medical sciences ; Myocardial Infarction - prevention & control ; Pharmacology. Drug treatments</subject><ispartof>European journal of drug metabolism and pharmacokinetics, 1994-01, Vol.19 (1), p.33-36</ispartof><rights>1994 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c311t-a9288b4df2aacd2f88e67cebe39c399cf957e009bf9e31c8eba9e1a07855444a3</citedby><cites>FETCH-LOGICAL-c311t-a9288b4df2aacd2f88e67cebe39c399cf957e009bf9e31c8eba9e1a07855444a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,778,782,27907,27908</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=4122852$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/7957449$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>VOICU, V</creatorcontrib><creatorcontrib>MIRCIOIU, C</creatorcontrib><creatorcontrib>JINGA, M</creatorcontrib><creatorcontrib>IONESCU, M</creatorcontrib><creatorcontrib>BURCEA, X</creatorcontrib><creatorcontrib>IONESCU, D. D</creatorcontrib><creatorcontrib>LUPESCU, G</creatorcontrib><title>Pharmacokinetic based adjustment of lidocaine antiarrhythmic schedule</title><title>European journal of drug metabolism and pharmacokinetics</title><addtitle>Eur J Drug Metab Pharmacokinet</addtitle><description>Administration of lidocaine, 200 mg/day i.m. or 275 mg orally, decreased sudden death after myocardial infarct (from 20.7% to 10.3%) although such schedules are not considered adequate to guarantee efficient plasma levels. Inclusion of lidocaine in a polyethylene matrix assured a slow release and complete disappearance of known side effects. Lidocaine was administered 200 mg intramuscularly to hospitalized patients every 6 h or 275 mg oral tablets to healthy volunteers every 8 h and plasma levels evaluated. Plasma levels after oral administration to healthy volunteers showed a great variability, so that it was not possible to draw a statistically significant conclusion about the accumulation of lidocaine in a period of 1 week. In coronary artery disease patients, plasma levels slowly increased with time, but clinical signs indicated, in some cases, a much more rapid accumulation. The therapeutic efficiency at low repeated doses was explained as a consequence of a slow accumulation on the one hand and of the addition of the action of MEGX, the major metabolite of lidocaine, on the other hand.</description><subject>Antiarythmic agents</subject><subject>Arrhythmias, Cardiac - complications</subject><subject>Arrhythmias, Cardiac - drug therapy</subject><subject>Biological and medical sciences</subject><subject>Cardiovascular system</subject><subject>Chromatography, Gas</subject><subject>Death, Sudden, Cardiac - prevention & control</subject><subject>Delayed-Action Preparations</subject><subject>Drug Administration Schedule</subject><subject>Humans</subject><subject>Injections, Intramuscular</subject><subject>Lidocaine - administration & dosage</subject><subject>Lidocaine - pharmacokinetics</subject><subject>Lidocaine - therapeutic use</subject><subject>Medical sciences</subject><subject>Myocardial Infarction - prevention & control</subject><subject>Pharmacology. Drug treatments</subject><issn>0378-7966</issn><issn>2107-0180</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1994</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpF0E1Lw0AQBuBFlFpqL96FHMSDEJ3dTbK7Ry2tCgU96DlMNhOSmo-6mxz674001LnMYR5ehpexaw4PHEA9Pm9Acq21gDM2FxxUCFzDOZuDVDpUJkku2dL7HYwjtYnjZMZmysQqisycrT9KdA3a7rtqqa9skKGnPMB8N_i-obYPuiKoq7yzOIIA275C58pDXzYj9rakfKjpil0UWHtaTnvBvjbrz9VruH1_eVs9bUMrOe9DNELrLMoLgWhzUWhNibKUkTRWGmOL8SsCMFlhSHKrKUNDHEHpOI6iCOWC3R1z9677Gcj3aVN5S3WNLXWDT1WiQYPQI7w_Qus67x0V6d5VDbpDyiH9qy39r23EN1PqkDWUn-hU0ni_ne7oLdaFw9ZW_sQiLoSOhfwFbux0sw</recordid><startdate>19940101</startdate><enddate>19940101</enddate><creator>VOICU, V</creator><creator>MIRCIOIU, C</creator><creator>JINGA, M</creator><creator>IONESCU, M</creator><creator>BURCEA, X</creator><creator>IONESCU, D. D</creator><creator>LUPESCU, G</creator><general>Médecine et hygiène</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19940101</creationdate><title>Pharmacokinetic based adjustment of lidocaine antiarrhythmic schedule</title><author>VOICU, V ; MIRCIOIU, C ; JINGA, M ; IONESCU, M ; BURCEA, X ; IONESCU, D. D ; LUPESCU, G</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c311t-a9288b4df2aacd2f88e67cebe39c399cf957e009bf9e31c8eba9e1a07855444a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1994</creationdate><topic>Antiarythmic agents</topic><topic>Arrhythmias, Cardiac - complications</topic><topic>Arrhythmias, Cardiac - drug therapy</topic><topic>Biological and medical sciences</topic><topic>Cardiovascular system</topic><topic>Chromatography, Gas</topic><topic>Death, Sudden, Cardiac - prevention & control</topic><topic>Delayed-Action Preparations</topic><topic>Drug Administration Schedule</topic><topic>Humans</topic><topic>Injections, Intramuscular</topic><topic>Lidocaine - administration & dosage</topic><topic>Lidocaine - pharmacokinetics</topic><topic>Lidocaine - therapeutic use</topic><topic>Medical sciences</topic><topic>Myocardial Infarction - prevention & control</topic><topic>Pharmacology. Drug treatments</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>VOICU, V</creatorcontrib><creatorcontrib>MIRCIOIU, C</creatorcontrib><creatorcontrib>JINGA, M</creatorcontrib><creatorcontrib>IONESCU, M</creatorcontrib><creatorcontrib>BURCEA, X</creatorcontrib><creatorcontrib>IONESCU, D. D</creatorcontrib><creatorcontrib>LUPESCU, G</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of drug metabolism and pharmacokinetics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>VOICU, V</au><au>MIRCIOIU, C</au><au>JINGA, M</au><au>IONESCU, M</au><au>BURCEA, X</au><au>IONESCU, D. D</au><au>LUPESCU, G</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pharmacokinetic based adjustment of lidocaine antiarrhythmic schedule</atitle><jtitle>European journal of drug metabolism and pharmacokinetics</jtitle><addtitle>Eur J Drug Metab Pharmacokinet</addtitle><date>1994-01-01</date><risdate>1994</risdate><volume>19</volume><issue>1</issue><spage>33</spage><epage>36</epage><pages>33-36</pages><issn>0378-7966</issn><eissn>2107-0180</eissn><abstract>Administration of lidocaine, 200 mg/day i.m. or 275 mg orally, decreased sudden death after myocardial infarct (from 20.7% to 10.3%) although such schedules are not considered adequate to guarantee efficient plasma levels. Inclusion of lidocaine in a polyethylene matrix assured a slow release and complete disappearance of known side effects. Lidocaine was administered 200 mg intramuscularly to hospitalized patients every 6 h or 275 mg oral tablets to healthy volunteers every 8 h and plasma levels evaluated. Plasma levels after oral administration to healthy volunteers showed a great variability, so that it was not possible to draw a statistically significant conclusion about the accumulation of lidocaine in a period of 1 week. In coronary artery disease patients, plasma levels slowly increased with time, but clinical signs indicated, in some cases, a much more rapid accumulation. The therapeutic efficiency at low repeated doses was explained as a consequence of a slow accumulation on the one hand and of the addition of the action of MEGX, the major metabolite of lidocaine, on the other hand.</abstract><cop>Genève</cop><pub>Médecine et hygiène</pub><pmid>7957449</pmid><doi>10.1007/BF03188820</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0378-7966 |
| ispartof | European journal of drug metabolism and pharmacokinetics, 1994-01, Vol.19 (1), p.33-36 |
| issn | 0378-7966 2107-0180 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_76808028 |
| source | MEDLINE; Springer Nature - Complete Springer Journals |
| subjects | Antiarythmic agents Arrhythmias, Cardiac - complications Arrhythmias, Cardiac - drug therapy Biological and medical sciences Cardiovascular system Chromatography, Gas Death, Sudden, Cardiac - prevention & control Delayed-Action Preparations Drug Administration Schedule Humans Injections, Intramuscular Lidocaine - administration & dosage Lidocaine - pharmacokinetics Lidocaine - therapeutic use Medical sciences Myocardial Infarction - prevention & control Pharmacology. Drug treatments |
| title | Pharmacokinetic based adjustment of lidocaine antiarrhythmic schedule |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T16%3A30%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pharmacokinetic%20based%20adjustment%20of%20lidocaine%20antiarrhythmic%20schedule&rft.jtitle=European%20journal%20of%20drug%20metabolism%20and%20pharmacokinetics&rft.au=VOICU,%20V&rft.date=1994-01-01&rft.volume=19&rft.issue=1&rft.spage=33&rft.epage=36&rft.pages=33-36&rft.issn=0378-7966&rft.eissn=2107-0180&rft_id=info:doi/10.1007/BF03188820&rft_dat=%3Cproquest_cross%3E76808028%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=76808028&rft_id=info:pmid/7957449&rfr_iscdi=true |